Timeline

Voting rights breakdown

Gemeldete wirtschaftlich Berechtigte · 25

Eine einzelne, gemeinsam eingereichte Meldung: Der Stimmrechtsanteil gilt für die gesamte Gruppe, nicht für jede Person.

• Aravis Venture I LP3%
• Astellas Venture Capital, LLC3%
• Auriga Ventures III3%
• Baltisches Haus Limited3%
• BioMedInvest II LP3%
• A/S Dansk Erhvervsinvestering3%
• Entrepreneurs Fund General Partners Limited3%
• Evolva Holding SA3%
• Mona Lisa Capital SA3%
• Novartis Bioventures Ltd3%
• Renaisance PME fondation suisse d investissement / Mona Lisa3%
• Sunstone Life Science Ventures Fund I K/S3%
• Symbion Capital I A/S3%
• Wellington Partners Ventures III Life Science Fund L.P3%
• Wellington Partners Ventures III Life Science Network Fund L3%
• Neil Goldsmith3%
• Alexandra SantAna Sørensen3%
• Pascal Longchamp3%
• Jakob Dynnes Hansen3%
• Jutta Heim3%
• PM Murali3%
• Ventureast Trustee Company P Limited3%
• APIDC Venture Capital P Limited3%
• Vaekstfonden3%
• Abunda SR, LLC3%

Notice details

Beneficial owner

Aravis Venture I LP

On 1 September 2011 the Lockup arrangement on Evolva shares ended. This arrangement has been in place since Evolva's listing in December 2009. Since 1 September 2011, most of the lockup participants have received their Evolva shares from the blocked depot. Any remaining shares have been de-blocked, leading to the termination of the lockup group and triggering the present disclosure.